Abstract. Transforming growth factor-ß1 (TGF-ß1) is overexpressed in a variety of malignant epithelial tumors and was suggested to be a marker of colorectal cancer. Moreover, there is growing evidence that TGF-ß1 contributes to tumor progression by regulating tumor cell proliferation and differentiation, inducing a favorable tumor microenvironment, promoting migration and invasion, and suppressing macrophage cytotoxicity. Therefore, we stably transfected an anti-TGF-ß1 hammerhead ribozyme into the human colorectal adenocarcinoma cell line HRT-18. Expression of this ribozyme resulted in significant inhibition of TGF-ß1 expression on mRNA and protein level. This was associated with an enhanced tumor cell differentiation and a reduced tumor growth in vivo. The capability of tumor cells to suppress ROI production of co-cultivated human macrophages was abrogated in transfectants. Taken together, inhibition of TGF-ß1 in colorectal carcinoma cells might be an interesting therapeutic tool leading to reduced tumor cell growth and increased macrophage cytotoxicity. Thus, a gene-therapeutic approach using anti-TGF-ß1 ribozyme in combination with established anti-tumor agents is of great promise.
Introduction
TGF-ß1 is one of the most important profibrogenic growth factors of the human body. This mediator is overexpressed in a variety of malignant tumors including ovarian (1), gastric (2) , colorectal (3), liver (4), breast (5) and prostate carcinoma (6) , malignant melanoma (7), glioblastoma (8) and pulmonary adenocarcinoma (9) . Moreover, more than two thirds of the patients with colorectal carcinoma have elevated TGF-ß1 plasma levels in comparison to healthy volunteers. Plasma TGF-ß1 levels increase with higher Dukes' stage (10) , and it has been shown that the TGF-ß1 level is of prognostic relevance in colorectal carcinomas, suggesting that this mediator plays a significant role in tumor progression (11, 12) .
In fact, TGF-ß1 modulates many aspects of tumor cell behavior ranging from tumor suppression at early stages to promotion of metastasis (13) . Colon carcinoma cells can switch their response to TGF-ß1 from repression of proliferation as it is the case in normal epithelial cells to growth stimulation during carcinoma progression (14) . This switch seems to be associated with mutations affecting at least one component of the TGF-ß signaling pathway (15) or with an activated JNK-pathway (16) . Additionally to this growth promoting role we have previously shown that TGF-ß1 is one of the key regulators of extracellular matrix composition (17) and therefore involved in formation of desmoplastic stroma which is typical for colorectal adenocarcinoma. TGF-ß1 also regulates integrin expression and acts as a motility factor (18) . Thus, an increased expression and activation of TGF-ß1 results in the formation of favorable tumor cell microenvironment promoting tumor migration. Also, the TGF-ß family is one of the most potent immunosuppressors described to date, since this mediator inhibits both cytotoxic lymphocytes and cytotoxicity of macrophages (19, 20) .
All these effects are mediated by a number of different pathways. Best known among them is the Smad-family, activated via TGF-ß-receptors on the cell surface. But TGF-ß can also activate the Erk, JNK and p38MAPK pathways (21) . Activation of MAPK was shown in Smad-deficient cells (22) and even mutated TGF-ß-receptor type I, defective in Smadactivation, mediated p38MAPK-activation by TGF-ß1 (23 promote proliferation. Finally, there are also hints for activation of phosphatidylinositol-3-kinase (PI3K), resulting in Akt-phosphorylation (24) , and for an interaction with protein phosphatase 2A (PP2A) (25) . TGF-ß1 has a variety of effects and its inhibition may fundamentally alter tumor cell proliferation, differentiation, microenvironment, invasion and host immune response. Therefore, we constructed a ribozyme to inhibit TGF-ß1 expression. We used HRT-18 colorectal adenocarcinoma cells, which produce and respond to TGF-ß1, to investigate effects of diminished TGF-ß1 expression in respect to cell growth in vitro. Furthermore, we focused on cell adhesion and reactive oxygen intermediates (ROI) production of macrophages in co-culture with ribozyme-transfected HRT-18 cells. Finally, we investigated xenografts of native and ribozyme-transfected HRT-18 cells in nude mice.
Materials and methods
Cell culture. The human colorectal adenocarcinoma cell line HRT-18 was obtained from Cell Lines Service (Heidelberg, Germany) and maintained in RPMI-1640 medium (Biochrom, Berlin, Germany) supplemented with 10% fetal calf serum (PAA, Cölbe, Germany). Monocyte isolation and cultivation as well as the co-culture model of MCTS (multicellular tumor spheroids) and macrophages were performed as described previously (20) . The 25F9 macrophage phenotype used in these experiments represents the mature fraction of human macrophages.
Design and synthesis of anti-TGF-ß1 hammerhead ribozyme
Ribozyme-mediated RNA cleavage in vitro. To design an anti-TGF-ß1 ribozyme, a GTC site in exon 7 at nucleotide 1983 within the coding sequence for the mature peptide of the human TGF-ß1 cDNA sequence (accession no. XO2812) was selected and tested according to Gibson and Shillitoe (26) . The ribozyme and its respective target sequence are shown in Fig. 1 .
Cleavage activity of this ribozyme was tested in a cellfree in vitro assay as described by Wichert et al (27) . Oligo sequence for the anti-TGF-ß1 ribozyme and primer sequences for amplification of truncated TGF-ß1 target transcript out of total cDNA of TGF-ß1 expressing HRT-18 cells are shown in Table I .
Plasmid construction and stable transfection of HRT-18 cells. The ribozyme sequence was cloned into the eukaryotic expression vector pcDNA3.1/V5/HIS-TOPO (Invitrogen, Carlsbad, USA). Correct sequence and orientation of the insert were confirmed by sequencing. Circular pcDNA3.1 vector without ribozyme served as a negative control (mock). Transfections were performed using TransFast TM according to the manufacturer's instructions (Promega, Mannheim, Germany). Several stable cell clones resistant to G418 sulfate (300 μg/ml) were selected after 3 weeks and expanded for screening of ribozyme-and TGF-ß1 expression. Each of the clones was separately analyzed and one representative mock and ribozyme clone chosen for detailed characterization in comparison to non-transfected HRT-18 cells. Table I . Primers used. 
Reverse transcription-polymerase chain reaction (RT-PCR);
real-time-PCR. Total RNA was isolated by the phenol/ isothiocyanate method using TRIzol-reagent (Gibco, Eggenstein, Germany). To compensate for variation in reverse transcription efficiency, cDNA from three independent reactions was pooled. Relative quantification of the TGF-ß1 mRNA was performed by real-time PCR using the LightCycler FastStart DNA Master SYBR Green I kit (Roche, Mannheim, Germany) according to the manufacturer's instructions in the presence of 3 mM MgCl 2 and the primers shown in Table I on a LightCycler ® instrument (Roche). The housekeeping gene aldolase served as an external standard. The annealing temperatures were 55 and 58˚C for TGF-ß1 and aldolase, respectively. Standards for TGF-ß1 and aldolase were generated by cloning their PCR products in the pCR2.1 vector (Invitrogen). Plasmids were cultured in E. coli using standard procedures. The Maxi-Prep kit (Qiagen, Hilden, Germany) was used to isolate and purify the vector. A quantification curve was calculated facilitating serial dilutions of the standard vectors (10 8 -10 3 copies) when amplified with the unknown samples within the same LightCycler run. Data calculations were performed by the second derivative maximum method. TGF-ß1 and aldolase copies were measured in three different runs and a ratio of TGF-ß1/aldolase copies was calculated. Only runs with an error <0.05 and an amplification efficiency ≥1.8 were accepted. The mean ratio and standard deviation of three runs is shown.
TGF-ß1 enzyme-linked immunosorbent assay (ELISA).
Supernatants of tumor cells were collected after 24 h of culture in serum-free medium, centrifuged and stored at -80˚C. TGF-ß1 concentrations were measured using the human Quantikine TM TGF-ß1 immunoassay (R&D Systems, Bad Nauheim, Germany).
Proliferation assay. Proliferation was assessed by counting the cells with a CASY cell counter (Schärfe Systems, Reutlingen, Germany). Cells were seeded in 6-well cluster plates and two wells of each clone were counted at days 2, 4, 6 and 9.
Adhesion assay. Microwell cluster plates (96) were coated with Matrigel ® Basement Membrane Matrix (Becton-Dickinson, Heidelberg, Germany) diluted in serum-free RPMI-1640 medium (1 mg/ml; 55 μl/well). Non-specific binding was blocked by incubating with 1% bovine serum albumin/PBS. Seven wells per group were plated with cells at a density of 3.5x10 4 cells/100 μl/well and incubated for 90 min at 37˚C with 5% CO 2 in a humidified incubator. Medium was aspirated, attached cells were fixed in 70% ethanol at -20˚C for 10 min and stained with crystal violet. After plates were rinsed with water, 0.2 Triton X-100/0.1 N HCl was added to solubilize the cells and the absorbance of the solution was measured at 590 nm.
Chemiluminescence assay. Production of ROI was measured on a Luminoskan RS luminometer (Labsystems, Helsinki, Finland) as described previously (20) . Briefly, macrophages were cultured in 96-well plates in the presence of tumor cells (ratio 10:1) for 24 h. ROI production was stimulated with 0.1 μM PMA 15 min after adding 100 μM Lucigenin to each well.
Xenografts in SCID-mice. Female BALB/c nude mice were purchased from Charles River Laboratories (Sulzfeld, Germany) and housed in an animal facility under specific pathogen-free conditions. All animal facilities and experiments were approved by local authorities. At the age of 6 weeks, 2.5x10 6 HRT-18 cells (native, ribozyme-transfected and mock clone, respectively) in 1xPBS solution were injected subcutaneously. In macrophage co-culture experiments, 2.5x10 5 cells of the 25F9 macrophage phenotype were added. Xenograft growth was measured twice a week and tumor volumes were calculated. On day 30, mice were sacrificed and tumors isolated. One half of each tumor was frozen in liquid nitrogen immediately, whereas the other half was fixed in 4% neutral-buffered formalin solution for immunohistochemical studies. TGF-ß1 mRNA expression was determined in a 5 mm cube of frozen tissue using realtime PCR as described previously.
Histological and immunohistochemical investigation of tumor tissue. Formalin-fixed tissue was processed using a routine wax-embedding procedure for histological examination, standard H&E slides were stained, and two pathologists independently analyzed tumor differentiation and the degree of necrosis.
For immunohistochemical staining cell pellets of native, ribozyme-transfected and mock clone HRT-18 cells were embedded in wax using standard procedures. Slides (2 μm) were deparaffinized using xylene and a series of alcoholwater solutions. Antigens were retrieved by incubation in citrate buffer (pH 6.0) for 5 min in a steam cooker. Staining was performed using Dako ChemMate detection kit K5005 (Dako, Hamburg, Germany) following the instruction manual. The following antibodies were used: ß-catenin (BD Transduction, Heidelberg, Germany, 1:5000), CEA (Novocastra/Leica Microsystems, Wetzlar, Germany, 1:100), E-cadherin (Dako, 1:50), MUC2 (Novocastra, 1:100), MUC4 (Zymed/Invitrogen, Karlsruhe, Germany, 1:100), MUC5AC (Novocastra, 1:50) and MUC6 (Novocastra, 1:50).
After haematoxylin counterstaining, slides were analyzed by two pathologists and the percentage of staining was determined.
Statistics. All data shown were obtained from at least three independent experiments and were expressed as mean ± SD Statistical significance of in vitro experiments was determined by Student's t-test, for xenograft growth by ANOVA trend test, and for TGF-ß1 expression as well as vital tumor masses in xenografts by Mann-Whitney U test. P-values <0.05 were considered to show a statistically significant difference.
Results
Ribozyme-mediated cleavage of truncated TGF-ß1 mRNA in a cell-free assay. The ability of the anti-TGF-ß1 ribozyme to cleave an in vitro transcribed truncated fragment of the TGF-ß1-encoding mRNA was shown in a cell-free system. The ribozyme degraded ~40% of the truncated TGF-ß1-encoding mRNA fragment after 1.5 h at physiological pH and temperature, with equimolar concentrations of ribozyme and TGF-ß1 mRNA (Fig. 2) .
Expression of anti-TGF-ß1 ribozyme and decreased expression of TGF-ß1 in HRT-18 cells.
Clones expressing anti-TGF-ß1 ribozyme (30) and 6 mock-transfected clones of the human colorectal adenocarcinoma cell line HRT-18 were isolated and TGF-ß1 expression was investigated. One representative clone of each group was selected for further detailed analysis.
Relative quantification of TGF-ß1 mRNA in relation to the house-keeping gene aldolase by real-time PCR showed diminished TGF-ß1 mRNA levels in the ribozyme clone, but increased TGF-ß1 mRNA level in the mock clone compared to HRT-18 cells without transfection. In parallel, secreted TGF-ß1 protein was reduced ~80% in the ribozyme clone measured by ELISA (Table II) .
Inhibition of TGF-ß1 results in a different growth pattern, minor changes in protein expression, reduced cell adhesion on Matrigel, but has no effect on proliferation in vitro. While native HRT-18 and mock cells grow as confluent monolayer, the ribozyme-transfected cell clone forms slightly exalted clusters (Fig. 3) .
Expression of a number of colorectal protein markers was slightly changed, ribozyme-transfected cells showed appearance of CEA (carcinoembryonic antigen), reduction of MUC5AC protein (mucin 5, subtypes A and C) and loss of MUC6 (mucin 6). All other proteins investigated showed no changes (Table III) .
Adhesion was measured on Matrigel, a reconstituted basement membrane. HRT-18 cells adhered poorly to plastic surfaces of the culture well. The adhesion of the diminished TGF-ß1-expressing ribozyme clone on Matrigel was significantly reduced by ~36%, whereas the adhesion of the mock clone with higher TGF-ß1 expression increased ~35% (Fig. 4) .
Proliferation investigated by cell counting over a period of 9 days showed no significant varieties of proliferation between untransfected HRT-18 cells, ribozyme-and mocktransfected clone in the presence of 10% fetal calf serum (data not shown). Table II . TGF-ß1 expression in HRT-18 and transfected cells. ----------------------------------------------------------------------------------------------------- a Measured by real-time PCR; b measured by human Quantikine TGF-ß1 immunoassay.
-----------------------------------------------------------------------------------------------------HRT-18 Mock Ribozyme -----------------------------------------------------------------------------------------------------
- Figure 2 . In vitro cleavage of a truncated TGF-ß1 RNA substrate by the anti-TGF-ß1 hammerhead ribozyme. Substrate (150 nM) was incubated with 150 nM ribozyme at 37˚C for 90 min in the presence of 12 mM MgCl 2 . Samples were size-fractionated on an 8% polyacrylamide gel containing 7 M urea. Cleavage products in the predicted size of 141 and 58 nt, and 199 nt substrate were identified by autoradiography. 
----------------------------------------------------------------------------------------------------

Effect of the ribozyme expression in HRT-18 MCTS on the production of ROI in co-culture with the 25F9 macrophage phenotype.
Previously, we showed the inhibition of ROI production of different macrophage phenotypes by HRT-18 cells as well as an inhibition of ROI by recombinant TGF-ß1 (20) . Now, we measured ROI production of the mature macrophage phenotype 25F9 in co-culture with MCTS of the ribozymetransfected HRT-18 clone and found that decreased expression of TGF-ß1 in HRT-18 cells causes abolishment of the inhibition of ROI production of 25F9 macrophage phenotype as observed with untransfected HRT-18 cell spheroids and the mock clone (Fig. 5) .
Xenografts of anti-TGF-ß1 ribozyme transfected tumor cells show reduced TGF-ß1 expression, but slightly enhanced tumor growth.
Xenografts of either native HRT-18 or ribozyme-transfected HRT-18 cells were generated with and without the addition of human macrophages, respectively. Xenografts of ribozyme-transfected cells showed in both cases a slightly increased tumor growth. Due to the limited number of animals this increase did not reach statistical significance (n=5, p=0.08, respectively). The addition of macrophages retarded tumor growth in native and ribozymetransfected xenografts whereas the ribozyme-transfected ones were statistically significant (p=0.03) despite the comparatively low number of cases (Fig. 6) . TGF-ß1 levels in the xenograft tumors were quantified to assess the sustainability of the ribozyme induced TGF-ß1-suppression. As expected, xenografts consisting of ribozymetransfected cells contained reduced TGF-ß1 levels compared to those of native HRT-18 cells. Due to the limited number of samples, this difference did not reach statistical significance (p=0.06). Xenografts of native or ribozymetransfected cells together with macrophages showed TGF-ß1 expression levels between those extremes, whereas the contribution rate of the two cellular fractions was not determined (Fig. 7) . Table III . Immunoreactive profile of native and ribozymetransfected HRT-18 cells. 
Vital tumor masses of xenografts of anti-TGF-ß1 ribozymetransfected tumor cells were lighter than that of native HRT-18 cells.
To account for the different degrees of necrosis observed in the xenografts, vital tumor masses were calculated based on total masses and percentages of necrosis. Weight of ribozyme-transfected xenografts was reduced to one third compared to tumors of native HRT-18 (n=5, p=0.09). This effect was slightly reduced when macrophages were added (Fig. 8) .
Discussion
TGF-ß1 is produced by a number of malignancies and has been suggested to be a prognostic marker as well as a therapeutic target in patients with colorectal carcinoma (28).
We constructed an anti-TGF-ß1 ribozyme and investigated its effects in stably transfected HRT-18 colorectal adenocarcinoma cells, which spontaneously produce this mediator. Additionally, we generated xenografts of these cells in nude mice, partly with addition of human macrophages.
Hammerhead ribozymes diminish gene expression by cleaving numerous copies of its respective mRNA-substrate (26) . The herein described anti-TGF-ß1 hammerhead ribozyme is directed against the human TGF-ß1 mRNA and does not cleave human TGF-ß2 or -ß3 mRNA (data not shown). We were able to show that this ribozyme has endoribonucleolytic activity in a cell-free system. Stable transfection resulted in a significant inhibition of TGF-ß1 expression on mRNA and protein level. Remarkably, TGF-ß1 expression was increased in all mock clones (which were transfected with the empty pcDNA3.1 vector) compared to untransfected HRT-18 control cells. We also found this vector effect in other cell lines (A27/80, OVCAR-3, 257P and 181P), which is in accordance with results from other authors (29) .
Although secretion of TGF-ß1 was reduced by 80% in the ribozyme clone, this inhibition did not change proliferation of HRT-18 cells in vitro. In contrast, other studies described a growth-inhibiting effect of TGF-ß1 in human colon carcinoma FET cells, mediated by TGF-ß1 antisense treatment (30) . Similar, negative growth regulation by TGF-ß1 was reported in a murine high-grade glioma model, in which TGF-ß inhibited tumor growth and enhanced apoptosis (31) . These effects are not surprising as TGF-ß1 physiologically inhibits proliferation in normal epithelial cells. However, in transformed cells TGF-ß1 usually has no anti-proliferative effect or might act as growth stimulator (32) . Effects of TGF-ß1 on proliferation are cell line-dependent and may even differ in various experimental settings. The determination whether TGF-ß1 has a positive or negative effect on proliferation is dependent on the current status of the TGF-ß1 signaling system as a whole. This comprises the amount of active TGF-ß1, expression of functional receptors and integrity of downstream signaling pathways (21, 33) . The resulting effect of TGF-ß1 seems to change during tumor progression in colon carcinoma (14) and was also investigated in a model of breast cancer progression (34) . In the latter case, a switch was described within a single cell line at different stages of carcinogenesis. Furthermore, TGF-ß has tumor-suppressive effects on normal epithelium and low-grade invasive cancer, but acts pro-metastatically in high-grade invasive cancer.
It has also been discussed, that TGF-ß1 is an important factor in regulation of cell adhesion molecules and extracellular matrix production. It is thought to play a role in the composition of the tumor stroma and for modulation of tumor cell migration. In TGF-ß1 antisense-transfected colon carcinoma FET cells ·5-integrin was reduced which led to reduced adhesion of tumor cells to fibronectin (35) . In our model, diminished TGF-ß1 expression in HRT-18 ribozyme clone significantly decreased adhesion of tumor cells to Matrigel basement membrane matrix. Similar results are described in hepatocellular carcinoma cells in which TGF-ß1 stimulated ·3-integrin expression and triggered invasiveness (36) .
In addition to these effects, it is known that TGF-ß1 acts as a very potent immunosuppressor. Together with other factors secreted by tumor cells, e.g. interleukin-10 or prostaglandin E2, it suppresses anti-tumor activity of immunocompetent cells which are no longer able to reject the tumor (19, 37) . Especially, tumor-associated macrophages are converted to an anti-inflammatory behavior and promote tumor cells (38) . A recent review summarized the immunosuppressive effects of TGF-ß1 on dendritic and effector T cells (39), whereas it had been shown that toxicity of cytotoxic T cells can be restored by TGF-ß depletion (40) . On the basis of these observations, inhibition of TGF-ß1 should attract inflammatory macrophages, restore cytotoxicity of T cells and hopefully switch the phenotype of tumor-associated macrophages back to an anti-tumor behavior. Support for this hypothesis comes from a study on the non-immunogenic rat prostate cancer line MATLyLu. After downregulation of TGF-ß1 by antisense strategy tumor incidence in normal rats was significantly decreased, whereas tumor incidence in immunodeficient rats was 100% (41) .
Anti-tumoral cytotoxicity of macrophages is partly exerted by ROI (42) , which can have anti-tumoral as well as tumor-promoting effects (43) . We have previously shown that HRT-18 cells suppress the production of ROI by human macrophages in an in vivo-like co-culture model (20) . Now we could demonstrate that this suppression is mediated in part by tumor-produced TGF-ß1. In our xenograft model, ribozyme-transfected tumors showed generally reduced vital tumor masses. This reduction was also seen in ribozymetransfected tumor cells in combination with human macrophages, although the experimental setting did not allow a clear differentiation between direct ribozyme-effects and overlapping effects of restored ROI production of tumorassociated macrophages. Nevertheless, inhibition of TGF-ß1 expression in tumor cells might maintain cytotoxic activities of tumor-associated macrophages in vivo.
Taken together, several effects of TGF-ß1 influence the behavior of tumors in vivo and result in different net effects. In our study, the constructed anti-TGF-ß1 ribozyme reduces cell adhesion and increases tumor necrosis in xenografts, with no significant changes in proliferation of the cell line HRT-18 used in this work. This positive correlation between TGF-ß1 and tumor progression is in accordance with other studies, i.e. in hepatocellular carcinoma (36) , pulmonary adenocarcinoma (9), prostate (6) and colon cancer (3, 10, 11, 32, 44) .
Apart from immediate effects on tumor cells, inhibition of TGF-ß1 would also diminish immunosuppressive effects on macrophages and enhance their cytotoxic ROI production in the microenvironment of tumors. This reconstitution of the locally suppressed immune system might be an important factor for tumor elimination in addition to established tumor agents.
